Article Text

Download PDFPDF

Introducing a new ESMO Open article series: how I treat side effects of immunotherapy
  1. Matthias Preusser
  1. Medical University of Vienna, Department of Medicine I, Division of Oncology, Vienna, Austria
  1. Correspondence to Matthias Preusser; matthias.preusser{at}meduniwien.ac.at

Statistics from Altmetric.com

Immunotherapy has revolutionised medical oncology due to durable responses and favourable clinical trial outcomes seen in some patient populations treated with immune checkpoint inhibitors.1 As a consequence, various immune checkpoint inhibitors have been approved by regulatory bodies and have quickly been adpoted as the standard treatment option in several cancer types, such as melanoma, lung cancer and renal cell cancer.2–8 Efficacy has been shown not only in metastatic stages including patients in highly advanced treatment phases but also in patients with lung cancer and melanoma treated in the adjuvant setting.9 Recent data from lung cancer, melanoma and glioblastoma indicate that immune checkpoint inhibition may even be of relevant clinical benefit in neoadjuvant therapy, thus opening novel avenues for further development of cancer immunotherapy.10–23 In addition, novel molecular insights drive refined selection of patients with cancer for targeted treatments including immunotherapies and the development of new approaches to effective anti-cancer immunomodulation.24–26 Notwithstanding the economical issues and implications,27–29 all of these developments lead to a quickly increasing number of patients with cancer being exposed to modern immunotherapy in clinical routine worldwide. As a consequence, the medical community is increasingly faced with immune-related side effects of these novel therapeutics in everyday practice. The mode of action of immune checkpoint inhibitors explains the particularly broad spectrum of side effects associated with their use.30–32 Type and severity of adverse effects seen in patients treated with inhibitors of CTLA4, PD1, PD-L1 and other immunomodulatory molecules vary greatly between patients and require a well-informed and individualised approach to maximise patient safety. The current series of articles aimed to provide concise summaries of the personal approach of key opinion leaders to specific immune-related toxicities with a focus on rare adverse effects such as neurological and rheumathological phenomena and may complement the comprehensive and well-accepted general guidelines published by international societies, including the European Society of Medical Oncology.33 We do hope that the articles serve our readership and contribute to the spread of expertise in the quickly moving field of cancer immunotherapy and ultimately better care of patients with cancer worldwide.

References

  1. 1.
  2. 2.
  3. 3.
  4. 4.
  5. 5.
  6. 6.
  7. 7.
  8. 8.
  9. 9.
  10. 10.
  11. 11.
  12. 12.
  13. 13.
  14. 14.
  15. 15.
  16. 16.
  17. 17.
  18. 18.
  19. 19.
  20. 20.
  21. 21.
  22. 22.
  23. 23.
  24. 24.
  25. 25.
  26. 26.
  27. 27.
  28. 28.
  29. 29.
  30. 30.
  31. 31.
  32. 32.
  33. 33.
View Abstract

Footnotes

  • Funding The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.

  • Competing interests MP has received honoraria for lectures, consultation or advisory board participation from the following for-profit companies: Bayer, Bristol-Myers Squibb, Novartis, Gerson Lehrman Group (GLG), CMC Contrast, GlaxoSmithKline, Mundipharma, Roche, Astra Zeneca, AbbVie, Lilly, Medahead, Daiichi Sankyo and Merck Sharp & Dome.

  • Patient consent for publication Not required.

  • Provenance and peer review Not commissioned; internally peer reviewed.

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.